Vitamin K antagonists in anticoagulant therapy of patients with cancer

Pol Arch Med Wewn. 2012;122(1-2):60-4.

Abstract

Venous thromboembolism (VTE) is a common complication of cancer. Prolonged use of low-molecular-weight heparin in cancer patients provides better VTE prophylaxis compared with vitamin K antagonists. Both therapeutic options have a similar safety profile. If patients on long-term oral anticoagulation are diagnosed with cancer, they should continue treatment with vitamin K antagonists.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Anticoagulants / therapeutic use*
  • Blood Coagulation / drug effects
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Humans
  • Neoplasms / complications*
  • Thromboembolism / drug therapy*
  • Thromboembolism / etiology
  • Venous Thrombosis / drug therapy*
  • Venous Thrombosis / etiology
  • Vitamin K / administration & dosage
  • Vitamin K / antagonists & inhibitors*

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Vitamin K